Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation

[European Heart Journal Supplements 2020;22:I13–I21, doi:10.1093/eurheartj/suaa104]

In the originally published version of this manuscript, there was an error in Table 1, Patients with atrial fibrillation and prior TIA or stroke in randomized trials: baseline data. The footnote should read: “^bEdoxaban 60 mg or 30 mg in patients fulfilling the dose reduction criteria.” instead of “^bEdoxaban 60 mg.”

This has now been corrected online. The publisher apologises for the error.